T-20: A model for novel anti-HIV drugs in development

AIDS Reader

Volumn 12, Issue 11, 2002, Pages 469-470

  Laurence, Jeffrey ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Drug development; HIV AIDS; T 20

Indexed keywords

ENFUVIRTIDE; TENOFOVIR DISOPROXIL;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; EDITORIAL; FATIGUE; GENETIC VARIABILITY; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NAUSEA; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; VIRUS CELL INTERACTION; VIRUS LOAD;

FEMALE; HIV ENVELOPE PROTEIN GP41; HIV INFECTIONS; HIV-1; HIV-2; HUMANS; PEPTIDE FRAGMENTS;

EID: 0036853552     PISSN: 10530894     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (11)

1. Wild C, Greenwell T, Matthews T. A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion. AIDS Res Human Retroviruses. 1993;9:1051-1053.
2. Derdeyn C, Decker J, Sfakianos J, et al. Sensitivity of human immunodeficiency virus type 1 to fusion inhibitors targeted to the gp41 first heptad repeat involves distinct regions of gp41 and is consistently modulated by gp120 interactions with the coreceptor. J Virol. 2001;75:8605-8614.
3. Cohen CJ, Dusek A, Green J, et al. Long-term treatment with subcutaneous T-20, a fusion inhibitor, in HIV-infected patients: Patients satisfaction and impact on activities of daily living. AIDS Patient Care STDS. 2002;16:327-335.
4. Poveda E, Rodes B, Toro C, et al. Evolution of the gp41 region in HIV-infected patients receiving T-20, a fusion inhibitor. AIDS. 2002;16:1959-1980.
5. Henry K, Lalezari J, OHearn M, et al. Enfuvirtide (T-20) in combination with an optimized background (OB) regimen vs OB alone in patients with prior experience or resistance to each of the three classes of approved antiretrovirals (ARVs) in North America and Brazil. In: Program and abstracts of the XIV International AIDS Conference; July 7-12, 2002; Barcelona, Spain. Abstract LbOr19B
6. Drobnes C, Fang L, Nelson E, et al. Tolerability of enfuvirtide (T-20) during chronic therapy in phase 2 trials. In: Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 27-30, 2002; San Diego. Abstract H-171.
7. Corey L, Tyring S, Beutner K, et al. Once daily valacyclovir reduces transmission of genital herpes. In: Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 27-30, 2002; San Diego. Abstract LB-3.
8. Moses AV, Jarvis MA, Raggo C, et al. Kaposi's sarcoma-associated herpesvirus-induced upregulation of the c-kit proto-oncogene, as identified by gene expression profiling, is essential for the transformation of endothelial cells. J Virol. 2002;76: 8383-8399.
9. Daar AS, Thorsteinsdottir H, Martin DK, et al. Top ten biotechnologies for improving health in developing countries. Nat Genet. 2002;32:229-232.
10. Laurence J. Preventing AIDS by targeting other STDs. AIDS Patient Care STDS. 1997;11:217-222.
11. Van Damme L, Ramjee G, Alary M, et al. Effectiveness of COL-1492, a non-oxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: A randomised controlled trial. Lancet. 2002;360:971-977.